Drug Trial Radar · NCT07858500
Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jan 31, 2027
Primary completion
Jun 30, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Astellas Pharma Europe Ltd.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is an unmet medical need to treat people with advanced cancer in the stomach, or where the food pipe joins the stomach. These conditions are known as advanced gastric cancer or advanced gastroesophageal cancer (GEJ for short). Zolbetuximab is an approved treatment for people with advanced stomach (gastric) cancer or advanced GEJ cancer. Some people with stomach or GEJ cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab works by attaching to the Claudin 18.2 protein in their tumor. This switches on the body's immune system to attack the tumor. The main aim of the study is to collect information about zolbetuximab and other cancer treatments in people with advanced gastric or GEJ cancer. This includes safety information, how long people respond to treatment and how long people live for without their cancer getting worse. This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). This study will use information from European and Canadian health registries and databases to learn more about people with advanced gastric or GEJ cancers who used zolbetuximab and other cancer treatments. The entire study will last about 4 years.
Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
- Metastatic Gastric Adenocarcinoma or Cancer
- Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
Zolbetuximab ExposureDrug
Real-world exposure to zolbetuximab.
Platinum-based Chemotherapy ExposureDrug
Real-world exposure to platinum-based chemotherapy.
1L Treatment Not Containing Zolbetuximab ExposureDrug
Real-world exposure to 1L treatment not containing zolbetuximab.
Fluoropyrimidine-based Chemotherapy ExposureDrug
Real-world exposure to fluoropyrimidine-based chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: real-world overall survival (rwOS)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: real-world progression-free survival (rwPFS)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: real-world time to next treatment (rwTTNT)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: real-world time to next treatment or death (rwTTNTD)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: real-world time to progression (rwTTP)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: real-world duration of response (rwDOR)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: real-world response rate (rwRR)Time frame: From the point of initiating 1L treatment, assessed up to 12 months
- Cohort A: real-world disease control rate (rwDCR)Time frame: From the point of initiating 1L treatment, assessed up to 12 months
- Cohort A: real-world tumor growth rate (rwTGR) prior to 1L treatmentTime frame: Day 1
- Cohort A: rwTGRTime frame: From point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of records of specified adverse events (AEs)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: duration of specified AEsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: time to first specified AE recordTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of participants with serious adverse events (SAEs)Time frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of SAEs experienced per participantTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of specific SAETime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of records per participant of specific SAETime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: time to first SAE recordTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of participants with inpatient hospitalizationsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of inpatient hospitalizations with ICU stay per participantTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of inpatient hospitalizations with admission via accident and emergency (A&E) per participantTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: duration of inpatient hospitalizationsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: primary diagnoses associated with inpatient hospitalizationsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of participants receiving at least one antiemeticTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: number of antiemetics prescribed or dispensed to participantsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: time to prescription or dispensation of any antiemetic drugsTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: type of antiemetic drug received immediately prior to 1L treatmentTime frame: Day 1
- Cohort A: type of antiemetic drug receivedTime frame: From the point of initiating 1L treatment, assessed up to 4 years
- Cohort A: antiemetic drugs received immediately prior to 1L treatmentTime frame: Day 1
- Cohort A: antiemetic drugs receivedTime frame: From the point of initiating 1L treatment, assessed up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Institution
Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.